XRlabs, a London-based surgical intelligence company, has secured €7.48 million ($8.4 million) in Seed funding to advance its artificial intelligence platform designed for operating room environments. The round was led by Playground Global, with participation from Eka Ventures.
Founded in 2024 by neurosurgeon Dr. Ali Haddad, XRlabs is developing AI-driven solutions that aim to enhance surgical decision-making and outcomes. The startup’s emergence reflects a growing intersection between medical expertise and artificial intelligence technology, where domain specialists are creating tools tailored to specific clinical challenges.
Expanding Teams and Regulatory Path
The freshly raised capital will support three primary objectives for the company. XRlabs plans to expand both its engineering and clinical teams, strengthening its capacity to develop and validate its platform. Additionally, the funding will accelerate the company’s progression through regulatory approval pathways in the United Kingdom, Europe, and the United States—a critical step for any medical technology company seeking market access.
The company intends to deepen its clinical evidence base by establishing partnerships with institutions across the globe. Building robust clinical data is essential for gaining regulatory approval and demonstrating the real-world value of surgical AI systems to healthcare providers.
Expertise-Driven Approach
The investment reflects confidence in a particular model of AI development within healthcare. According to Bruce Leak, an investor perspective on the funding, “The best physical AI companies come from people who’ve experienced a problem in their field firsthand and have the deep expertise to know how to fix it.”
XRlabs exemplifies this principle, with Dr. Haddad bringing firsthand experience from the operating room itself. This insider perspective allows the startup to develop solutions grounded in practical surgical challenges rather than theoretical applications of artificial intelligence technology.
Broader Market Opportunity
The funding round comes as healthcare institutions across Europe increasingly seek technological solutions to improve surgical efficiency and patient outcomes. Surgical AI represents one of the most immediately applicable areas for artificial intelligence in healthcare, addressing challenges such as real-time decision support, procedure optimization, and outcomes prediction.
The European startup ecosystem has seen growing investment in surgical and medical technology in recent years, with companies addressing specific clinical needs attracting substantial backing from both generalist venture capital firms and specialized healthcare-focused investors. London continues to serve as a hub for healthtech innovation within Europe, drawing talent and investment capital focused on medical technology development.
As XRlabs progresses through its regulatory pathways, the company’s evolution will likely provide insights into how European regulators approach surgical AI technologies. The startup’s focus on building clinical evidence alongside product development suggests a methodical approach to proving the value of its platform in actual clinical settings, a requirement that increasingly distinguishes successful medical technology companies from those that struggle to achieve market traction.